Contact Us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right. 


123 Street Avenue, City Town, 99999

(123) 555-6789


You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

Dr Sofia Toniolo




Clinical RESEARCH FELLOW, DPHil Student

I am a fully trained Neurologist with a special interest in Alzheimer’s Disease, which led me to do research alongside my clinical training for the last 5 years in Rome. I have a strong background in Alzheimer’s disease biomarkers, ranging from Cerebrospinal fluid (CSF) and plasma analysis to PET and MRI imaging, which I’ve used to predict the susceptibility of the brain to evolve from a healthy state to its pathological counterpart. I have also contributed to investigate how CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival according to the patients’ ApoE status.

I have spent my last year of training at the Clinical Imaging Sciences Centre in Brighton under the supervision of Prof M. Cercignani and Dr. Marco Bozzali, investigating volumetric, diffusion and functional connectivity changes that can be detected through MRI imaging in the cerebellum of patients with Alzheimer’s disease. After passing the European Board Examination in Neurology in Lisbon in 2018, which is a sign of excellence in the assessment of European neurological education I became a Fellow of the European Board of Neurology.

I am now working as a Clinical Research Fellow in Cognitive Neuroscience under the supervision of Prof. Masud Husain through a grant funded by the Wellcome Trust and I have just started a DPhil in Clinical Neurosciences at the University of Oxford. My research focuses on short term memory deficits patients with Alzheimer’s disease and how does ApoE status relates to MRI and short term memory changes in patients with subjective cognitive impairment, mild cognitive impairment and Alzheimer’s disease, in order to help tackling the disease at its earliest stage.